Norpen Oro (Olanzapine)

Olanzapine, the active ingredient in Norpen Oro, is a second‑generation (atypical) antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia and for managing manic episodes of bipolar disorder in adult patients under medical supervision and through a prescription. GNH USA supplies Norpen Oro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance across EU and global markets.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychotic and mood disorders. - Schizophrenia: Reduces psychotic symptoms such as delusions, hallucinations, and thought disorder. - Bipolar disorder (manic episodes): Controls acute manic symptoms and stabilizes mood. - Schizoaffective disorder: Improves both psychotic and mood components of the illness.

Common Side Effects: - Weight gain: Increased appetite and body weight. - Sedation: Drowsiness or feeling of tiredness. - Metabolic changes: Elevated blood glucose or lipid levels. - Dry mouth: Reduced salivation. - Constipation: Decreased bowel motility. - Extrapyramidal symptoms: Tremor or stiffness (less frequent). Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: Severe reduction in white blood cells. - Hyperglycaemia: Marked increase in blood sugar requiring medical attention. - Seizures: Rare occurrence of convulsive episodes.

Olanzapine requires careful monitoring in several clinical situations. - Cardiovascular risk: Assess for orthostatic hypotension and monitor blood pressure. - Metabolic monitoring: Regularly check weight, fasting glucose, and lipid profile. - Hepatic function: Use with caution in patients with liver impairment. - Elderly patients: Increased sensitivity to sedation and anticholinergic effects. - Pregnancy and lactation: Evaluate risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Olanzapine may interact with several medications that affect its metabolism or additive side‑effects. Major Interactions (Avoid): - Strong CYP1A2 inducers (e.g., rifampicin, carbamazepine): May reduce olanzapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): Can enhance sedation and respiratory depression. Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): May increase olanzapine concentrations. - Anticholinergic agents: May exacerbate dry mouth and constipation. - QT‑prolonging drugs: Potential additive effect on cardiac repolarisation.